Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04108156
Other study ID # GR40550
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 30, 2019
Est. completion date February 28, 2025

Study information

Verified date April 2024
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 634
Est. completion date February 28, 2025
Est. primary completion date September 19, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years at time of signing Informed Consent Form - Documented diagnosis of diabetes mellitus (Type 1 or Type 2) - HbA1c level of =10% within 2 months prior to screening or at screening Study eye - Macular thickening secondary to DME involving the center of the fovea with CST =325 um on SD-OCT at screening - BCVA score of 78 to 25 letters (20/32 to 20/320 approximate Snellen equivalent) Exclusion Criteria: - High-risk proliferative diabetic retinopathy - Active intraocular inflammation (grade trace or above) - Suspected or active ocular or periocular infection of either eye - Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study - Cerebrovascular accident or myocardial infarction within 6 months prior to randomization - Atrial fibrillation diagnosis or worsening within 6 months prior to randomization - Uncontrolled blood pressure

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Will be administered as per the schedule described in individual arm.
Intravitreal Ranibizumab 0.5 mg Injection
Will be administered as per the schedule described in individual arm.

Locations

Country Name City State
United States Retina Res Institute of Texas Abilene Texas
United States Texas Retina Associates Arlington Texas
United States Western Carolina Retinal Associate PA Asheville North Carolina
United States Southeast Retina Center Augusta Georgia
United States Austin Clinical Research LLC Austin Texas
United States Austin Research Center for Retina Austin Texas
United States Austin Retina Associates Austin Texas
United States California Retina Consultants Bakersfield California
United States Johns Hopkins Med; Wilmer Eye Inst Baltimore Maryland
United States The Retina Care Center Baltimore Maryland
United States Retina & Vitreous of Texas Bellaire Texas
United States Retina-Vitreous Associates Medical Group Beverly Hills California
United States Envision Ocular, LLC Bloomfield New Jersey
United States Ophthalmic Consultants of Boston Boston Massachusetts
United States Tufts Medical Center Boston Massachusetts
United States Cumberland Valley Retina Consultants; Chambersburg Chambersburg Pennsylvania
United States Char Eye Ear &Throat Assoc Charlotte North Carolina
United States Mid Atlantic Retina Cherry Hill New Jersey
United States Midwest Vision Research Foundation Chesterfield Missouri
United States Retina Group of Washington Chevy Chase Maryland
United States Northwestern Medical Group/Northwestern University Chicago Illinois
United States Cincinnati Eye Institute Cincinnati Ohio
United States Cleveland Clinic Foundation; Cole Eye Institute Cleveland Ohio
United States The Ohio State University Columbus Ohio
United States Texas Retina Associates Dallas Texas
United States Midwest Retina Dublin Ohio
United States Duke Eye Center Durham North Carolina
United States Retina Vitreous Center Edmond Oklahoma
United States The Retina Partners Encino California
United States Eye Center of Northern CO Fort Collins Colorado
United States Retina Group of Florida Fort Lauderdale Florida
United States National Ophthalmic Research Institute Fort Myers Florida
United States Texas Retina Associates Fort Worth Texas
United States Retina Consultants of Orange County Fullerton California
United States Charles Retina Institute Germantown Tennessee
United States Associated Retinal Consultants Grand Rapids Michigan
United States Foundation for Vision Research Grand Rapids Michigan
United States Cumberland Valley Retina Associates Hagerstown Maryland
United States Long Is. Vitreoretinal Consult Hauppauge New York
United States Graystone Eye Hickory North Carolina
United States Illinois Retina Associates Joliet Illinois
United States Charleston Neuroscience Inst Ladson South Carolina
United States Colorado Retina Associates, PC Lakewood Colorado
United States Retina Associates Lenexa Kansas
United States Retina Associates of Kentucky Lexington Kentucky
United States Retina Vit Surgeons/Central NY Liverpool New York
United States Piedmont Eye Center Lynchburg Virginia
United States Georgia Retina PC Marietta Georgia
United States Barnet Dulaney Perkins Eye Center Mesa Arizona
United States Vitreo Retinal Surgery Minneapolis Minnesota
United States Carolina Eyecare Physicians Mount Pleasant South Carolina
United States N CA Retina Vitreous Assoc Mountain View California
United States Tennessee Retina PC Nashville Tennessee
United States New York University New York New York
United States Wagner Kapoor Institute Norfolk Virginia
United States University Retina and Macula Associates, PC Oak Forest Illinois
United States East Bay Retina Consultants Oakland California
United States Ophthalmic Cons of Long Island Oceanside New York
United States California Eye Specialists Medical group Inc. Pasadena California
United States Doheny Eye Institute Pasadena California
United States Retina Specialty Institute Pensacola Florida
United States Arizona Retina and Vitreous Consultants Phoenix Arizona
United States Associated Retina Consultants Phoenix Arizona
United States Retinal Consultants of Arizona Phoenix Arizona
United States Fort Lauderdale Eye Institute Plantation Florida
United States Maine Eye Center Portland Maine
United States Retina Northwest Portland Oregon
United States Sierra Eye Associates Reno Nevada
United States Retina Institute of Virginia Richmond Virginia
United States Retinal Consultants Med Group Sacramento California
United States The Retina Institute Saint Louis Missouri
United States Retina Vitreous Assoc of FL Saint Petersburg Florida
United States Retina Associates of Utah, PLLC Salt Lake City Utah
United States Rocky Mountain Retina Salt Lake City Utah
United States Med Center Ophthalmology Assoc San Antonio Texas
United States Zuckerberg San Francisco General Hospital San Francisco California
United States Orange County Retina Med Group Santa Ana California
United States California Retina Consultants Santa Barbara California
United States Retina Center Northwest Silverdale Washington
United States Spokane Eye Clinical Research Spokane Washington
United States Southern Vitreoretinal Assoc Tallahassee Florida
United States Retina Associates of Florida, LLC Tampa Florida
United States Retina Associates of NJ Teaneck New Jersey
United States Retina Consultants of Texas The Woodlands Texas
United States Retina Specialists Towson Maryland
United States Retina Group of New England Waterford Connecticut
United States Palmetto Retina Center, LLC West Columbia South Carolina
United States Wolfe Eye Clinic West Des Moines Iowa

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured using the ETDRS chart in the efficacy population using a treatment policy strategy for all intercurrent events BCVA = Best-Corrected Visual Acuity
ETDRS = Early Treatment Diabetic Retinopathy Study
A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
Baseline to Week 64
Secondary Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured with use of the ETDRS chart in the modified intent-to-treat (mITT) population using a treatment policy strategy for all intercurrent events ETDRS-DRSS = ETDRS Diabetic Retinopathy Severity Scale Baseline to Week 64
Secondary Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured with use of the ETDRS chart in the mITT population using a hypothetical strategy for all intercurrent events Baseline to Week 64
Secondary Percentage of participants with a =2-step improvement from baseline on the ETDRS-DRSS at Week 64 in the efficacy population Baseline to Week 64
Secondary Percentage of participants with a =2-step improvement from baseline on the ETDRS-DRSS at Week 64 in the mITT population Baseline to Week 64
Secondary Change from baseline in BCVA as measured on the ETDRS chart over time Baseline up to Week 120
Secondary Percentage of participants who lose <15, <10, and <5 letters in BCVA from baseline over time Baseline up to Week 120
Secondary Percentage of participants who gain =15, =10, =5, =0 letters in BCVA from baseline over time Baseline up to Week 120
Secondary Percentage of participants with a BCVA Snellen equivalent of 20/40 or better over time Baseline up to Week 120
Secondary Percentage of participants with a BCVA Snellen equivalent of 20/200 or worse over time Baseline up to Week 120
Secondary Percentage of participants with a =2-step improvement from baseline on the ETDRS-DRSS over time Baseline up to Week 120
Secondary Percentage of participants with a =3-step improvement from baseline on the ETDRS-DRSS over time Baseline up to Week 120
Secondary Time to =2-step worsening from baseline on the ETDRS-DRSS Baseline up to Week 120
Secondary Time to =3-step worsening from baseline on the ETDRS-DRSS Baseline up to Week 120
Secondary Change from baseline in ETDRS-DRSS score over time Baseline up to Week 120
Secondary Change from baseline in CST as measured on SD-OCT over time Baseline up to Week 120
Secondary Change from baseline in total macular volume as measured on SD-OCT over time Baseline up to Week 120
Secondary Percentage of participants with absence of intraretinal fluid over time (intraretinal fluid as measured in the central 1 mm subfield) Baseline up to Week 120
Secondary Percentage of participants with absence of subretinal fluid over time (subretinal fluid as measured in the central 1 mm subfield) Baseline up to Week 120
Secondary Percentage of participants with absence of intraretinal fluid and subretinal fluid over time Baseline up to Week 120
Secondary Percentage of participants with absence DME (defined as CST =325 µm on SD-OCT) over time DME = diabetic macular edema Baseline up to Week 120
Secondary Time to PDR (defined as a score =60 on the ETDRS-DRSS) PDR = proliferative diabetic retinopathy Baseline up to Week 120
Secondary Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab within each refill-exchange interval Baseline up to Week 120
Secondary Percentage of participants who report preferring PDS treatment compared with intravitreal ranibizumab treatment As measured by the PDS Patient Preference Questionnaire at Week 64 among patients in the PDS arm efficacy population, mITT population Baseline to Week 64
Secondary Percentage of participants who report preferring PDS treatment compared with intravitreal ranibizumab treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 64 Participants in in a subset of patients with bilateral disease who are simultaneously receiving ranibizumab via study eye PDS implant and fellow eye intravitreal injection Baseline to Week 64
Secondary Patient-reported vision-related functioning and health-related quality of life (HRQoL) among patients in both treatment arms, as measured by changes from baseline As measured by in the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite score and Near Activities, Distance Activities, and Driving subscale scores , Baseline Week 48, Week 96
Secondary Patient-reported vision-related functioning and HRQoL, as measured by the proportion of patients with a = 4-point improvement from baseline in the NEI VFQ-25 composite score at Weeks 48 and 96 among patients in both treatment arms Baseline, Week 48, Week 96
Secondary Incidence and severity of ocular adverse events Baseline to Week 120
Secondary Incidence and severity of non-ocular adverse events Baseline up to Week 120
Secondary Incidence, severity, and duration of adverse events of special interest Baseline up to Week 120
Secondary Serum concentration of ranibizumab observed over time Baseline up to Week 120
Secondary PK parameter value area under the concentration- time curve over 24 weeks (AUC24W) Baseline to Week 24
Secondary Pharmacokinetic (PK) parameter maximum serum concentration (Cmax) Baseline up to Week 120
Secondary PK Parameter minimum serum concentration (Cmin) Baseline up to Week 120
Secondary Time of maximum observed serum concentration (Tmax) after PDS implant insertion Baseline up to Week 120
Secondary Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study Baseline up to Week 120
Secondary Prevalence of neutralizing antibodies at baseline and incidence of neutralizing antibodies during the study Baseline up to Week 120
Secondary Reported incidence of device deficiencies Baseline up to Week 120
Secondary Incidence and severity of ocular adverse events Baseline up to Week 120
Secondary Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (up to 37 days after initial implantation) and follow-up period (> 37 days after implantation surgery) Baseline up to Week 120
Secondary Incidence and severity of adverse device effects Baseline up to Week 120
Secondary Incidence, causality, severity, and duration of anticipated serious adverse device effects Baseline up to Week 120
See also
  Status Clinical Trial Phase
Completed NCT03953807 - A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated Phase 4
Completed NCT03622580 - A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Phase 3
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Terminated NCT04611152 - A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Terminated NCT04603937 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Withdrawn NCT03629210 - Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema Phase 2
Withdrawn NCT02842541 - Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema Phase 1
Completed NCT02221453 - Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide Phase 2
Completed NCT02979665 - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Completed NCT02000102 - Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab N/A
Completed NCT02088229 - Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema N/A
Terminated NCT00779142 - Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies N/A
Completed NCT01171976 - Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Phase 3
Completed NCT00989989 - Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Phase 3
Completed NCT01259609 - Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy N/A
Terminated NCT00768040 - Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Phase 2
Completed NCT00683176 - Effect of Choline Fenofibrate (SLV348) on Macular Edema Phase 2
Active, not recruiting NCT00801450 - Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery Phase 1/Phase 2